Literature DB >> 27376400

Apatinib for the treatment of gastric cancer.

Giandomenico Roviello1,2, Andrea Ravelli3, Anna Ida Fiaschi4, Maria Rosa Cappelletti2, Angela Gobbi2, Chiara Senti2, Laura Zanotti2, Karol Polom5, Andrew R Reynolds6, Stephen B Fox7, Daniele Generali2,8.   

Abstract

INTRODUCTION: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models. AREAS COVERED: Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer. Expert commentary: Unfortunately, as yet, there is no definitive biomarker data for apatinib in gastric cancer.

Entities:  

Keywords:  Gastric cancer; VEGFR2; angiogenesis; apatinib; chemotherapy

Mesh：

Substances：

Year:  2016        PMID： 27376400     DOI： 10.1080/17474124.2016.1209407

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


  27 in total

1.  Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.

Authors:  Shucheng Chen; Lan Yao
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-12       Impact factor: 3.333

2.  Identification of an antitumor effect of demethylzeylasteral on human gastric cancer cells.

Authors:  Yang Yang; Menglin Zhao; Ting Hu; Fang Su; Feng Qian; Zishu Wang
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

3.  Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.

Authors:  Qian Xie; Jing Wang; Wenwen Wu; Ye Zhao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 4.  Prospects of circular RNAs: the regulators of drug resistance and metastasis in gastric cancer.

Authors:  Bingyu Wang; Zihao Chen; Wenbo Liu; Bibo Tan
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

5.  Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.

Authors:  Chao Xu; Xiaoli Xie; Ning Kang; Huiqing Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

6.  Apatinib regulates the growth of gastric cancer cells by modulating apoptosis and autophagy.

Authors:  Xu Liu; Qiaoyu Zheng; Qiongfang Yu; Yan Hu; Yanmin Cheng; Zhaozhao Shao; Li Chen; Wenjie Ding; Dian Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-18       Impact factor: 3.000

7.  The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.

Authors:  Giandomenico Roviello; Roberto Petrioli; Pietro Rosellini; Andrea Giovanni Multari; Raffaele Conca; Giovanni Paganini; Giorgio Chiriacò; Michele Aieta
Journal:  Invest New Drugs       Date:  2019-01-28       Impact factor: 3.850

8.  Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.

Authors:  Yong Wang; Wenke Li; Nianliang Jing; Xiangji Meng; Shizhen Zhou; Yufang Zhu; Jun Xu; Rongjie Tao
Journal:  Cancer Biol Ther       Date:  2020-03-25       Impact factor: 4.742

9.  Apatinib has anti-tumor effects and induces autophagy in colon cancer cells.

Authors:  Wu Lu; He Ke; Ding Qianshan; Wang Zhen; Xiang Guoan; Yu Honggang
Journal:  Iran J Basic Med Sci       Date:  2017-09       Impact factor: 2.699

Review 10.  [Mechanism and Prospect of Radiotherapy Combined with Apotatinib
in the Treatment of Non-small Cell Lung Cancer].

Authors:  Guohui Liu; Chunbo Wang; Mingyan E
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.